Arbutus Biopharma (ABUS) Assets Average (2011 - 2026)

Arbutus Biopharma (ABUS) has reported Assets Average for 15 consecutive years, with $185.9 million the latest figure, recorded in Q1 2026.

• Quarterly Assets Average rose 49.48% year-over-year to $185.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.9 million (up 49.48% YoY) and the FY2025 annual result came in at $113.2 million, down 18.03% from the prior year.
• Assets Average advanced to $185.9 million in Q1 2026 per ABUS's latest filing, from $96.2 million in the prior quarter.
• Over the last five years, Assets Average for ABUS reached as high as $226.4 million in Q2 2022 and fell as low as $96.2 million in Q4 2025.
• A 5-year average of $162.3 million and a median of $155.2 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average jumped 60.76% — and 2025, when it plunged 33.12%.
• Year by year, Assets Average stood at $199.6 million in 2022, then dropped by 24.09% to $151.5 million in 2023, then fell by 10.19% to $136.1 million in 2024, then slipped by 29.33% to $96.2 million in 2025, then jumped by 93.31% to $185.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $185.9 million, $96.2 million, and $100.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.